-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOMEA FUSION INC: ICOVAMENIB WAS GENERALLY WELL TOLERATED, WITH NO NEW OR UNEXPECTED SAFETY SIGNALS IDENTIFIED THROUGHOUT 52-WEEK OBSERVATION PERIOD

Reuters·04/27/2026 21:37:38

Please log in to view news